Bristol Myers Squibb’s Camzyos shows sustained efficacy in 56-week pediatric heart disease trial

• Bristol Myers Squibb presented 56-week Phase 3 SCOUT-HCM results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.
• Treatment sustained reductions in heart outflow obstruction, with meaningful symptom improvements consistent with earlier results.
• No new safety signals emerged; no participants experienced the specified decline in the heart’s pumping function during follow-up.
• The FDA cleared Camzyos in September 2026 for pediatric patients weighing at least 30 kilograms, based on earlier 28-week results.
• Additional clinical and real-world findings will be presented at the American Heart Association’s Scientific Sessions, November 6-9, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202611061600BIZWIRE_USPR_____20261105_BW324472) on November 06, 2026, and is solely responsible for the information contained therein.